DaVita logo

DaVita(DVA)

Leader

US kidney care leader with ~3,000 dialysis centers; $12.8B FY2024 revenue; 237,000 US patients 3x/week; Berkshire Hathaway ~40% stake; GLP-1 drugs may reduce ESRD prevalence long-term.

77
AI Score
Grade B
AI Visibility Score (Beta)
HealthcareEnterpriseDVAWebsiteUpdated March 2026

Brand Intelligence Graphcompany

Company Overview

About DaVita

DaVita Inc. is the leading kidney care company in the United States, providing dialysis services to patients with chronic kidney failure and end-stage renal disease (ESRD), founded in 1994 as Total Renal Care and rebranded as DaVita in 2000 after acquiring Gambro Healthcare. Headquartered in Denver, Colorado and trading on NYSE (DVA), DaVita generated approximately $12.8 billion in revenues for FY2024 under CEO Javier Rodriguez, operating approximately 3,000 outpatient dialysis centers across the United States serving approximately 237,000 patients, plus international operations in 13 countries. Berkshire Hathaway holds approximately 40% of DaVita's common shares—a major Warren Buffett investment thesis built on the essential, recurring nature of ESRD treatment, which patients require three times per week for life unless they receive a kidney transplant.

Business Model & Competitive Advantage

DaVita's business is structurally tied to Medicare reimbursement: approximately 80% of its U.S. dialysis revenues come from government payers (Medicare and Medicaid), with CMS (Centers for Medicare & Medicaid Services) setting the ESRD Prospective Payment System (PPS) bundled rate annually. The company's strategic focus on in-center and home dialysis modalities—peritoneal dialysis and home hemodialysis—reflects both clinical preferences for home care and the potential for lower facility costs. DaVita's Home program, branded DaVita at Home, has expanded capacity following CMS incentives that pay modestly higher rates for home dialysis patients. Physician partnership programs and integrated kidney care arrangements with managed care plans provide diversified revenue streams beyond fee-for-service dialysis.

Competitive Landscape 2025–2026

In 2025-2026, DaVita navigates multiple structural challenges and opportunities: GLP-1 obesity drugs (Ozempic, Wegovy) may reduce the prevalence of type 2 diabetes—the leading cause of ESRD—over a 15-20 year horizon, creating a long-term secular headwind that investors are beginning to price into dialysis company valuations. Annual Medicare rate setting remains the primary earnings lever, with CMS-proposed rates for 2024-2025 providing modest inflation adjustments that trail actual cost growth. Fresenius Medical Care (FME) is DaVita's primary U.S. competitor, operating approximately 2,600 U.S. dialysis centers, while U.S. Renal Care (private) is a regional competitor. DaVita's strong brand, scale, and patient satisfaction scores support its leadership position in an essential healthcare service category.

Founded
1994
Headquarters
Denver, Colorado, United States
Revenue
$12.8B
Curated content • Fact-checked and verified

The DaVita Story

Founded in 1994
Denver, Colorado, United States
Founded by Various founders as Total Renal Care, Inc.

Founders

Various founders as Total Renal Care, Inc.

Recent Activity

View all →

Company Timeline

Major milestones in DaVita's journey

14
Total Events
3
Acquisitions

Leadership Team

Meet the leaders behind DaVita

Javier J. Rodriguez

Chief Executive Officer & Director

Javier Rodriguez has served as CEO and Executive Director of DaVita since June 1, 2019. He joined DaVita in 1998 and served in numerous leadership roles before becoming CEO of DaVita Kidney Care in 2014. Rodriguez succeeded Kent Thiry, who led the company's remarkable turnaround from 1999-2019, and has continued to drive clinical excellence and operational efficiency. He brings over 25 years of kidney care industry experience.

Joel Ackerman

Chief Financial Officer & Treasurer

Joel Ackerman has served as Chief Financial Officer and Treasurer of DaVita since 2019, overseeing all financial operations, strategy, capital allocation, and investor relations. He has been instrumental in managing the company's strong cash flow generation, share repurchase programs, and financial performance through both operational challenges and strategic transitions.

Madhu Narasimhan

Chief Information Officer

Madhu Narasimhan joined DaVita as Chief Information Officer in 2024, leading the company's technology strategy, digital transformation initiatives, and information systems. He oversees IT infrastructure, cybersecurity, data analytics, and technology-enabled innovations in patient care delivery.

Kent J. Thiry

Former CEO & Executive Chairman (1999-2019)

Kent Thiry served as CEO from October 1999 to June 2019, leading DaVita's remarkable transformation from near-bankruptcy to industry leadership. He orchestrated the company's rebranding to DaVita in 2000, established the values-driven village culture, and oversaw the transformative Gambro Healthcare acquisition in 2005. He transitioned to Executive Chairman in 2019 before fully retiring, leaving a legacy of clinical excellence and cultural innovation.

Key Differentiators

Market Leader

DaVita is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.

Enterprise Scale

With $12.8B in revenue, DaVita operates at enterprise scale with proven market validation.

Frequently Asked Questions

Estimated Visibility Trend (Beta)

Simulated 8-week rolling score

77
→ Stable

Based on estimated brand signals. Historical tracking coming soon.

Similar Brands

Idexx Laboratories logo

Idexx Laboratories

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu

GE HealthCare logo

GE HealthCare

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin

Incyte logo

Incyte

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,

Biogen logo

Biogen

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com

Danaher Corporation logo

Danaher Corporation

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man

Revvity logo

Revvity

Healthcare Tech
B2bHealthtechManufacturingSaasPublic

Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid

Compare DaVita with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For DaVita

Claim This Profile

Are you from DaVita? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim DaVita Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention DaVita vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →